Compare STRS & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | SGHT |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.4M | 235.0M |
| IPO Year | 1994 | 2021 |
| Metric | STRS | SGHT |
|---|---|---|
| Price | $28.96 | $5.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 81.2K | ★ 129.1K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 512.50 | 28.16 |
| EPS | ★ 0.82 | N/A |
| Revenue | $29,914,000.00 | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $35.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.35 | $3.11 |
| 52 Week High | $32.93 | $9.24 |
| Indicator | STRS | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 61.60 |
| Support Level | $28.51 | $4.76 |
| Resistance Level | $29.99 | $5.66 |
| Average True Range (ATR) | 0.96 | 0.30 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 90.55 | 95.52 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.